Serum S100B levels in children with simple febrile seizures  by Atici, Yeliz et al.
Seizure 21 (2012) 175–177Serum S100B levels in children with simple febrile seizures
Yeliz Atici a, Fu¨sun Alehan a, Taner Sezer a,*, Nilden Tuygun b, Ays¸ egu¨l Haberal c,
Ays¸ e Can Yazici d, Can Demir Karacan b
aDivision of Pediatric Neurology, Baskent University School of Medicine, Ankara, Turkey
bDepartment of Pediatrics, Dr Sami Ulus Women and Children’s Health and Diseases Training and Research Hospital, Ankara, Turkey
cHematology Laboratory, Baskent University Faculty of Medicine, Ankara, Turkey
dDepartment of Biostatistics, Baskent University Faculty of Medicine, Ankara, Turkey
A R T I C L E I N F O
Article history:
Received 14 April 2011
Received in revised form 21 November 2011
Accepted 22 November 2011
Keywords:
Astroglial activation
Epilepsy
Febrile convulsion
S100B
A B S T R A C T
Purpose: Recent studies have found that S100B is a useful marker for astroglial activation seen in various
neurologic disorders. The purpose of this study was to evaluate whether simple febrile seizures (SFS) was
associated with an elevation in serum S100B levels.
Methods: In this study the samples consisted of 39 patients with SFS ranging from 6 to 36 months of age, and
age-matched and sex-matched controls including 30 patients with fever and 30 healthy subjects. Two
serum samples were obtained for S100B from the study group at 0–1 h and 6–24 h following seizure. Serum
samples were drawn once in the control group. The serum samples were then analyzed using ELISA.
Results: In the study group, the mean values of the serum S100B concentrations at 0–1 h and 6–24 h were
32.6  7.8 pg/ml and 32.1  5.8 pg/ml, respectively, while the concentrations were 32.1  8.8 pg/ml and
29.5  7.8 pg/ml in the control groups. No signiﬁcant differences were detected in serum S100B levels at 0–
1 h or 6–24 h in the study when compared to the control groups.
Conclusions: These results suggest that SFS do not raise serum S100B concentration above the normal
range.
 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Febrile seizures (FS) are the most common convulsive disorder
during childhood with a prevalence in children of approximately
3–4%. FS usually develop in children from six months to ﬁve years
of age following an increase in body temperature higher than
38 8C.1 Based on the seizure type FS are divided into simple and
complex. Simple febrile seizures (SFS) are single and generalized
seizures with a duration lasting less than 15 min. Complex febrile
seizures are partial, or, prolonged seizures that repeat within 24 h.
Although the prognosis associated with FS is generally considered
good, the long-term effects of FS on brain development have not
yet been clearly identiﬁed, particularly its effects associated with
neuronal damage and neurocognitive functions.2–4 The relation-
ship between FS and mesial temporal sclerosis (MTS) has been one
of the most contentious issues in epileptology. For instance, some
evidence suggests that prolonged FS directly damage the
hippocampus and surrounding structures, while other authors
contend that an independent underlying pathology may be
responsible for FS and development of MTS.5,6* Corresponding author at: Oguzlar Mah. 1381, sok. no: 11-4, Balgat, Ankara,
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doi:10.1016/j.seizure.2011.11.003A number of proteins have been proposed as peripheral
biochemical markers of neuronal damage and glial activation
including S100B and neuron speciﬁc enolase (NSE). Therefore, the
concentrations of these molecules in the blood and central nervous
system (CNS) may represent an important step forward in the
diagnosis and monitoring of CNS diseases. S100B is a calcium
binding protein found primarily in the astroglial and Schwann
cells.7,8 Previous studies found that the serum S100B concentra-
tions were elevated and associated with the severity of adverse
neurologic outcome in hypoxic and traumatic brain damage as
well as ischemic stroke.9,10 There are some reports on the
evaluation of serum S100B concentrations in adults with epilepsy
including temporal lobe epilepsy (TLE), symptomatic and idio-
pathic partial epilepsies, but the results are diverging.11,12
While several studies have examined the serum NSE levels in
FS, no studies have yet examined the S100B levels in FS. Therefore,
the purpose of this study was to investigate whether SFS affects the
serum concentration of S100B.
2. Methods
The present study included thirty-nine children with SFS and
sixty control subjects who were admitted to the pediatric
emergency department of our hospital between September 2009
and March 2010. Children were deﬁned as febrile seizure patientsvier Ltd. All rights reserved.
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38 8C or higher. Simple febrile seizures were deﬁned as generalized
tonic, tonic–clonic or atonic activity without focal features, shorter
than 15 min duration without recurrence subsequent 24 h. All the
patients were admitted to our emergency room within 30 min
after the initiation of febrile seizure. Intracranial infections were
excluded by clinical or laboratory ﬁndings, and lumbar punctures
were performed in 24 of 39 patients. All patients were followed in
the emergency room for at least 24 h. The control group was
composed of 30 patients who had a fever without a seizure (control
a) and 30 healthy subjects (control b). Both groups were age- and
sex-matched according to the study group. The exclusion criteria
for this study included children who had evidence of history of
febrile seizures, metabolic diseases, developmental retardation,
and head trauma or a febrile seizure three days prior to admission.
This study was approved by the Ethics Committee of Baskent
University, and informed consent was obtained from all patients’
legal guardians before patient enrolment in the study.
Two serum samples were obtained for S100B from study group
at 0–1 h (0.7  0.12) and 6–24 h (9  0.4) following seizure. Serum
samples were drawn once in the control groups. All the blood samples
were centrifuged for 10 min at 3000 rpm, and the serum was frozen at
80 8C until the assays were performed. S100B (Headquarters
BioVendor Medical, Germany) specimens were analyzed using a
human S100B Enzyme-linked Immuno Sorbent Assay (ELISA). Serum
S100B concentration is expressed as pg/ml (mean  SD), and we
found that 95% of healthy individuals displayed serum S100B levels
lower than 50 pg/ml.
The Statistical Package for the Social Sciences version 17.0 (SPSS
Inc., Chicago, IL, USA) was used for data analysis. Levene test was
used to analyze variance homogeneity. Mann–Whitney’s U test
was used to compare two independent groups. Wilcoxon test was
employed to compare two independent groups, and Kruskal–
Wallis was used to compare groups containing more than two
independent groups. Spearman correlation coefﬁcients were also
calculated to examine bivariate relationships, and the correlation
between biochemical parameters and S100B concentrations of the
study groups was conducted using Spearman’s coefﬁcient. For the
two-way analysis, Pearson chi-square test, probability ratio test or
Fisher’s Exact test were used. A P-value less than 0.05 was deemed
signiﬁcant.
3. Results
Our study included 39 children (17 males, 22 females) with
simple febrile seizure, and the controls included 30 children (13
males, 17 females) in control group a and 30 children (13 males, 17
females) in control group b. The age of the subjects in this study
ranged from 6 to 36 months (17.4  7.3 months) in the study group,
6 to 36 months (17  9.4 months) in control group a, and 6 to 37
months (17.1  9.8 months) in the control group b. No statistically
signiﬁcant difference was detected between the groups for sex or age
(Table 1).Table 1
Demographic, clinical and biochemical data of subjects.
Study group (n = 39) 
Age (month)  SD 17.4  7.3 
Fever (8C)  SD 38.9  0.4*
Gender (% male) 56 
S100B (pg/ml) (0–1 h) (6–24 h)
SD 32.6  7.8* 32.1  5.8*
Median 31.3 31.3 
Minimum 20.3 24.7 
Maximum 54.4 51.6 
* P < 0.05.Table 1 shows serum S100B levels in study group and control
groups. No signiﬁcant differences were observed between the
mean S100B serum concentrations at 0–1 h (32.6  7.8 pg/ml) and
6–24 h (32.1  5.8 pg/ml) in the study group. In addition, no
signiﬁcant differences were found in serum S100B concentrations
between the study group, control group a (32.1  8.8 pg/ml) and
control group b (29.5  7.8 pg/ml).
The frequency and duration of febrile convulsion were as
follows: 1 min (1 patient), 2 min (4 patients), 3 min (4 patients),
5 min (19 patients), and 10 min (11 patients). No correlation was
detected between the duration of febrile seizures and S100B
concentrations (P = 0.605, rho: 0.085). When the children were
divided into two groups according to the duration of FS (seizure
duration 5 min or shorter versus seizure duration longer than
5 min), the serum S100B concentrations between the groups were
similar (31.9  8.6 pg/ml and 32.1  1.7 pg/ml, respectively). Finally,
S100B concentrations were not correlated with age and sex.
4. Discussion
S100B is a cytokine produced and released predominantly by
astrocytes in the CNS.8 In previous studies, elevated S100B
concentrations were associated with various neurological diseases,
such as minor and severe head injury, subarachnoid hemorrhage,
cerebral infarction, neurodegenerative processes and CNS infec-
tions.9,13,14 In addition, animal models of epilepsy and postsurgery
brain specimens from epileptic patients also showed elevated
brain tissue S100B concentrations.15,16 However, there are only a
limited number of studies examining serum S100B concentrations
in patients with epilepsy. For example, Portela et al. found normal
serum S100B levels in patients with focal epilepsy,12 while Lu et al.
reported elevated plasma S100B concentrations in patients with
TLE when compared with controls.11 In our study, we found no
signiﬁcant elevation of serum S100B concentrations in patients
with SFS.
The association between febrile seizures and TLE is a
controversial topic. Some retrospective studies conﬁrm such a
link between febrile seizures and TLE,6 while other studies indicate
that no link exists between the diseases.17 For example, Lu et al.
showed elevated serum S100B concentrations in twenty-eight TLE
patients when compared to healthy controls.11 However, febrile
seizure history data was not analyzed in this study. Therefore,
prospective studies that investigate serum S100B concentrations
in TLE patients with or without febrile seizures may help interpret
these ﬁndings.
The peak S100B levels have been reported within the ﬁrst 24 h
in hypoxic brain damage after traumatic brain injury.9 In the
present study, we measured S100B concentrations at 0–1 h to
serve as a baseline and at 6–24 h to detect a possible delayed post-
seizure elevation.
Neuron-speciﬁc enolase is another biochemical marker of
neuronal damage. Elevated rates of NSE have been demonstrated
in different neurologic insults such as anoxia, stroke and epilepsy.Control a (n = 30) Control b (n = 30)
17  9.4 17.1  9.8
38.8  0.4* 36.4  0.2
56 56
32.1  8.8* 29.5  7.8*
29.9 27.8
20.4 17.4
64.3 48.3
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time points after FS have not been shown.18 However, Tanabe et al.
found that both the NSE level in the CSF and the ratio of the CSF to
serum NSE levels showed strong correlations with seizure duration
in patients with complex febrile seizures.19 To our knowledge, the
present study is the ﬁrst detailed study examining serum S100B
concentrations after onset of febrile seizures.
In prior studies, it was shown that the blood–CSF barrier does
not affect the passage of S100B from the CSF to serum.20 While
plasma S100B levels reﬂect CSF S100B levels, we did not measure
CSF S100B levels due to ethical reasons in the present study.
Although S100B is highly brain speciﬁc and the highest
concentrations of S100B are found in astroglia and Schwann cells,
low concentrations can be found in neuroectodermal and
mesodermal tissues outside the CNS. Routsi et al. found increased
levels of serum S100B in critically ill patients without brain
injury.21 In addition to healthy volunteers, our study included
patients with fever who served as a control group in order to
exclude the possibility of effect of fever on release of S100B from
CNS or other tissues.
One limitation of our study is the lack of inclusion regarding the
patients with complex febrile seizures and febrile status. de Oliveira
et al. showed elevated CSF S100B levels 24 h after pilocarpine-
induced status epilepticus in rats.22 In addition, complex febrile
seizures have shown to be a risk factor for developing epilepsy, and
patients with prolonged febrile seizures and febrile status are
included in most of the studies which examine the effect of febrile
seizures on the hippocampus. Our study found similar serum S100B
levels in children who had seizures 5 min or less versus longer than
5 min, and these results suggest that the seizure duration does not
effect the S100B levels in SFS.
In conclusion, the present results show that SFS is not associated
with elevated serum S100B concentration. This ﬁnding suggests that
SFS does not cause astroglial activation; however, no other studies
have measured serum S100B in patients with febrile seizures.
Therefore, further studies on this subject are required to assess
S100B levels comparing simple and complex febrile seizures.
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